CSF biomarkers of AD co-pathology were not different between the groups (except for higher p-tau181 values in controls compared to asymptomatic GBA1 carriers), indicating that the observed group differences within the cholinergic system are largely independent of AD pathological processes. This evidence concerns the gene GBA1 and Alzheimer disease.